VTVT vs. HRTX, ACIU, SLS, GNFT, IPHA, EPRX, RAPT, VYGR, CCCC, and TNYA
Should you be buying vTv Therapeutics stock or one of its competitors? The main competitors of vTv Therapeutics include Heron Therapeutics (HRTX), AC Immune (ACIU), SELLAS Life Sciences Group (SLS), GENFIT (GNFT), Innate Pharma (IPHA), Eupraxia Pharmaceuticals (EPRX), Rapt Therapeutics (RAPT), Voyager Therapeutics (VYGR), C4 Therapeutics (CCCC), and Tenaya Therapeutics (TNYA). These companies are all part of the "pharmaceutical products" industry.
vTv Therapeutics vs. Its Competitors
Heron Therapeutics (NASDAQ:HRTX) and vTv Therapeutics (NASDAQ:VTVT) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, media sentiment, earnings, profitability, analyst recommendations, risk, institutional ownership and dividends.
vTv Therapeutics has a net margin of 0.00% compared to Heron Therapeutics' net margin of -0.62%. Heron Therapeutics' return on equity of 0.00% beat vTv Therapeutics' return on equity.
In the previous week, vTv Therapeutics had 3 more articles in the media than Heron Therapeutics. MarketBeat recorded 4 mentions for vTv Therapeutics and 1 mentions for Heron Therapeutics. Heron Therapeutics' average media sentiment score of 1.43 beat vTv Therapeutics' score of 0.00 indicating that Heron Therapeutics is being referred to more favorably in the media.
Heron Therapeutics has higher revenue and earnings than vTv Therapeutics. Heron Therapeutics is trading at a lower price-to-earnings ratio than vTv Therapeutics, indicating that it is currently the more affordable of the two stocks.
80.0% of Heron Therapeutics shares are owned by institutional investors. Comparatively, 17.5% of vTv Therapeutics shares are owned by institutional investors. 5.9% of Heron Therapeutics shares are owned by company insiders. Comparatively, 1.3% of vTv Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Heron Therapeutics has a beta of 1.22, meaning that its stock price is 22% more volatile than the S&P 500. Comparatively, vTv Therapeutics has a beta of 0.64, meaning that its stock price is 36% less volatile than the S&P 500.
Heron Therapeutics currently has a consensus target price of $4.50, suggesting a potential upside of 238.35%. vTv Therapeutics has a consensus target price of $35.50, suggesting a potential upside of 88.13%. Given Heron Therapeutics' higher probable upside, equities analysts clearly believe Heron Therapeutics is more favorable than vTv Therapeutics.
Summary
Heron Therapeutics beats vTv Therapeutics on 10 of the 15 factors compared between the two stocks.
Get vTv Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for VTVT and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding VTVT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
vTv Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:VTVT) was last updated on 9/4/2025 by MarketBeat.com Staff
Free VTVT Stock Alerts